Orexo completes the acquisition of Biolipox, appoints new CEO and publishes a prospectus

Orexo AB has today completed the previously announced acquisition of Biolipox AB. Orexo has acquired all shares and warrants in Biolipox through payment consisting of 7.630.895 new shares in Orexo and 926.000 warrants entitling to subscription for 926.000 new shares in Orexo.

The board of directors of Orexo has, in connection with the acquisition, appointed Torbjörn Bjerke as new CEO of the company. Torbjörn Bjerke was previously CEO in Biolipox. As previously announced Zsolt Lavotha, former CEO, will leave his employment and serve as Senior Advisor to Orexo’s board.

The board of directors of Orexo has prepared a prospectus regarding listing of shares in Orexo in connection with the acquisition of Biolipox. The prospectus is available at www.orexo.se. The prospectus can also be obtained, free of charge, from Orexo AB, Box 303, Virdings allé 32 A, 751 05 Uppsala, Sweden, tel. +46 (0)18-780 88 00.

For more information, please contact:
Håkan Åström, Chairman of the Board, Orexo AB
Tel: +46 (0)703-74 72 13
E-mail: hakanastrom@aol.com

Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com

Claes Wenthzel, Executive Vice President & CFO, Orexo AB
Tel: +46 (0)18-780 88 44
Email: claes.wenthzel@orexo.com